Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05329337
Other study ID # NIMAO/2020-1/PC-01
Secondary ID 2021-A03189- 32
Status Completed
Phase N/A
First received
Last updated
Start date June 27, 2022
Est. completion date October 5, 2023

Study information

Verified date November 2023
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a two-center proof-of-concept study, ancillary to the MetACTIV study, whose objective is to define immune activation profiles from the data of individuals followed by the Caisse Primaire d'Assurance Maladie du Gard (health insurance fund). The IRACTIV study will include a subset of volunteers from the MetACTIV study for whom a blood sample will be taken as part of the IRACTIV study.


Description:

The local health insurance fund regularly offers people who have already had a free health check-up the opportunity to re-do a check-up. This invitation will be made as part of the routine, by mail. People who have participated in the MetACTIV study will be asked to participate in the present IRACTIV study ( they will be sent an information note). That way, up to 30 volunteers who previously participated in the MetACTIV study, including 10 for whom a particular profile has been identified will be recruited again in sequence. On the day of consultation at the Gard health insurance fund, consent will be collected from subjects who have agreed to participate. The participation of the volunteers will be reduced to this single visit and 16 mL of blood will be collected on EDTA for the purpose of this study. As in the previous MetACTIV study, this blood will be transported to the Biological Resource Center at Nîmes University Hospital. From this blood, the plasma will be frozen and stored at -80°C for subsequent determination of insulin levels under the same conditions as for the MetACTIV study. Peripheral blood mononuclear cells will be frozen and, later, cultured at the Institute of Human Genetics in complete medium for 48 hours. The effect of the supernatants of these cultures on Akt phosphorylation in HepG2 cells exposed to 10nM of insulin will then be quantified by two different techniques (Western Blot and ELISA). This effect will be expressed as a percentage of inhibition compared to the phosphorylation of Akt induced by insulin alone. The insulin slope between the measurement performed in the MetACTIV study and this IRACTIV study will also be calculated and compared to the peripheral blood mononuclear cells ability to induce insulin resistance in vitro.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date October 5, 2023
Est. primary completion date October 5, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Individuals who participated in the MetACTIV study. - Profile 2 subgroup-specific inclusion criteria: - MetACTIV study individual with a Profile 2. - Persons who have given free informed consent. - Persons who have signed the consent form. - Persons affiliated to or benefiting from a health insurance plan. - Adults (=18 years of age). Exclusion Criteria: - Persons participating in Category 1 research involving human subjects - Persons in an exclusion period as determined by another study. - Persons under court protection, guardianship or trusteeship. - Persons who are incapable of giving consent. - Persons for whom it is impossible to give clear information. - Pregnant, parturient or breastfeeding woman.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Blood test
Sixteen mL of blood will be collected on EDTA for the purpose of this study

Locations

Country Name City State
France Caisse Primaire d'Assurance Maladie du Gard Nîmes Gard
France Centre Hospitalier Universitaire Nîmes Gard

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes Caisse Primaire d'Assurance Maladie du Gard

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Age of Profile 2 patients In years Day 0
Other Weight of profile 2 patients In kg Day 0
Other Gender of Profile 2 patients male / female Day 0
Other Waist measurement of Profile 2 patients In cm Day 0
Other Hip circumference of Profile 2 patients In cm Day 0
Other Systolic blood pressure in Profile 2 patients In mmHg Day 0
Other Diastolic blood pressure in Profile 2 patients In mmHg Day 0
Other High-density lipoproteins in Profile 2 patients mM/L Day 0
Other Low-density lipoproteins in Profile 2 patients mM/L Day 0
Other Triglycerides in Profile 2 patients mM/L Day 0
Other Hemoglobin A1c in Profile 2 patients mM/L Day 0
Primary Fasting blood glucose Fasting blood glucose will be measured during a routine health evaluation and measured in mM/L. Day 0
Primary End-of-study insulinemia The amount of insulin in the blood of patients will be measured during a routine health evaluation and measured in µU/L. Month 18
Primary Effect of peripheral blood mononuclear cell supernatant on intensity of the signal induced by insulin in hepatocytes. Peripheral blood mononuclear cells are isolated on a Ficoll gradient and frozen. These frozen peripheral blood mononuclear cells will be sent to the Institute of Human Genetics for culture and supernatants will be recovered after 48 hours. The effect of these supernatants on insulin signaling will then be tested. To do so, they will be added or not to cultured HepG2 cells stimulated 24 hours later by 10nM insulin. After stimulation, HepG2 cells will be lysed and their total Akt and phosphorylated Akt content measured by ELISA and Western Blot. The proportion of phosphorylated Akt in HepG2 cells exposed to peripheral blood mononuclear cells supernatant will be compared with the proportion of phosphorylated Akt in HepG2 cells not exposed to peripheral blood mononuclear cells supernatant and expressed as the percentage of insulin signaling inhibition induced by the peripheral blood mononuclear cells supernatant. Hour 48
Secondary A. Percentage inhibition of Akt phosphorylation in Profile 2 patients compared with other immune profiles. The decrease in signal intensity induced in hepatocytes by insulin induced by peripheral blood mononuclear cell supernatant from volunteers with Profile 2 will be compared to the decrease in this intensity induced by peripheral blood mononuclear cell supernatant from volunteers with another immune activation Profile. Measured as a percentage. Hour 48
Secondary B. Increase in insulinemia over time in Profile 2 patients compared with other immune profiles. Insulinemia in Profile 2 volunteers, measured in µU/mL, will be compared with that of other immune profiles. Month 18
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03383822 - Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04203238 - Potato Research for Enhancing Metabolic Outcomes N/A
Recruiting NCT03658564 - Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance N/A
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03627104 - Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT01809288 - Identifying Risk for Diabetes and Heart Disease in Women
Completed NCT04642482 - Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Withdrawn NCT04741204 - Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Phase 4
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A